Other substances

Tiopronin

A reducing cysteine derivate.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Tiopronin is a glycine derivate with reducing properties (NCIt). It is used for treatment of severe cystinuria and for chelation of copper particles in Wilson's disease (DrugBank).

Tiopronin on PubChem
Tiopronin on Wikipedia


Marketed as

ACADIONE; CAPEN; CAPTIMER; EPATIOL; KAI NA; MUCOSYT; SUTILAN; THIOLA; VINCOL

 

Structure image - Tiopronin

CC(C(=O)NCC(=O)O)S

Supporting references

Link Tested on Impact factor Notes Publication date
Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
Small molecule In vitro 		in vitro binding assay; HEK 293T cells; Vero E6 cells; Calu-3 cells 10.16

Disrupted ACE2-RBD (of SARS-CoV-2 spike protein) interaction and inhibited RBD binding to ACE2 on cell surface in vitro in dose-dependent manners. Did not inhibit viral entry, however.

 Nov/18/2020
Export (.csv)